Exposure-Response to SC Ustekinumab In Moderate-Severe Crohn's Disease: Results From the IM-UNITI Maintenance Study

被引：1
|
作者：
Adedokun, Omoniyi J. [1 ]
Xu, Zhenhua [1 ]
Gasink, Christopher [2 ]
Jacobstein, Douglas [1 ]
Szapary, Philippe [1 ]
Johanns, Jewel [1 ]
Gao, Long Long [2 ]
Davis, Hugh M. [1 ]
Hanauer, Stephen [3 ]
Feagan, Brian G. [4 ]
Ghosh, Subrata [5 ]
Sandborn, William J. [6 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA
[4] Western Univ, Robarts Res Inst, London, ON, Canada
[5] Inst Translat Med, Birmingham, W Midlands, England
[6] Univ Calif, La Jolla, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2017年 / 112卷
关键词：
D O I：
10.14309/00000434-201710001-00660
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
660
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [21] IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
    Travis, Simon
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (01): : 1 - 3
  • [22] Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 studies
    Adedokun, O. J.
    Xu, Z.
    Gasink, C.
    Friedman, J.
    Szapary, P.
    Lang, Y.
    Johanns, J.
    Gao, L. -L.
    Miao, Y.
    Davis, H.
    Hanauer, S.
    Feagan, B.
    Sandborn, W.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S23 - S24
  • [23] LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH TWO YEARS
    Sandborn, William J.
    Rutgeerts, Paul
    Gasink, Christopher
    Jacobstein, Douglas
    Gao, Long-Long
    Johanns, Jewel
    Sands, Bruce E.
    Hanauer, Stephen B.
    Targan, Stephan R.
    Ghosh, Subrata
    de Villiers, Willem J.
    Colombel, Jean Frederic
    Feagan, Brian G.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [24] Cost Reduction Associated With Improvement in Work Productivity Loss From Ustekinumab Treatment by Disease Severity States in Crohn's Disease Patients: Results From the IM-UNITI Clinical Trial
    Teeple, Amanda
    Muser, Erik
    Naessens, Dominik
    Lueza, Beranger
    Kamal, Zahra
    Colonier, Astrid Foix
    Carlucci, Claudia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S233 - S233
  • [25] Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohn's disease
    Sharma, Shringi
    Xin, Yan
    Gao, Yuying
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S36 - S36
  • [26] Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
    Li, K.
    Hayden, K.
    Wadman, E.
    Bhagat, S.
    Emrich, S.
    Friedman, J. R.
    Gasink, C.
    Brodmerkel, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S26 - S27
  • [27] Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohn's Disease: Results From IM-UNITI Long-Term Extension Through 2 Years
    Sands, Bruce E.
    Kramer, Brian
    Gasink, Christopher
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Gao, Long-Long
    Rutgeerts, Paul
    Ghosh, Subrata
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S329 - S329
  • [28] Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn's disease: results from IM-UNITI long-term extension through 2 years
    Ghosh, S.
    Kramer, B. C.
    Gasink, C.
    Jacobstein, D.
    Adedokun, O. J.
    Gao, L. -L.
    Rutgeerts, P.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S459 - S460
  • [29] Long-term (5-year) maintenance of clinically meaningful improvement in health-related quality of life in patients with moderate to severe Crohn's disease treated with ustekinumab in the IM-UNITI long-term extension study
    Sandborn, William J.
    Ghosh, Subrata
    Han, Chenglong
    Gasink, Christopher
    Zou, Bin
    Feagan, Brian G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 108 - 109
  • [30] LONG-TERM (5-YEAR) MAINTENANCE OF CLINICALLY MEANINGFUL IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE IM-UNITI LONG-TERM EXTENSION STUDY
    Sandborn, William J.
    Ghosh, Subrata
    Han, Chenglong
    Gasink, Christopher
    Zou, Bin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2021, 160 (06) : S558 - S559
12345